DMXAA, a mouse STING agonist, has been reported to possess strong antitumor activity in mouse but failed in clinical trials because it is unable to activate human STING.59–62 cGAMP has been recently proved to restrict tumor progression.17 Nevertheless, intravenous injection with high daily doses of cGAMP leads to only modest efficacy due to the poor transmembrane ability of cGAMP,21 which usually needs cell permeabilization for its intracellular delivery. Here, STING1 is linked to neoplasm.